TGF-β participates choroid neovascularization through Smad2/3-VEGF/TNF-α signaling in mice with Laser-induced wet age-related macular degeneration

Xiaolei Wang1,2, Wei Ma2,3, Song Han2, Zhaoyang Meng1, Lu Zhao1, Yi Yin1, Yanling Wang1 & Junfa Li2

Choroidal neovascularization (CNV) is the most severe complication in Age-related macular degeneration (AMD) and the most common cause of irreversible blindness in the elderly in developed world. The aim of this study was to identify the effect of transforming growth factor-β (TGF-β) and Smad2/3-VEGF/TNF-α signaling on CNV angiopoiesis, and to explore TGF-β inhibitors on the development of CNV in a CNV mouse model. Fundus fluorescein angiography (FFA) was used to evaluate the laser-induced CNV formation. The histology of CNV lesions stained with hematoxylin-eosin (HE) was obtained. The immunofluorescent staining was performed to determine TGF-β protein expression. The expressions of TGF-β, phosphorylated Smad2/3, VEGF and TNF-α were determined by using Western blot analysis. The CNV areas were analyzed by using fluorescein stain on RPE/choroid-sclera flat mounts. We found the levels of TGF-β protein expression increasingly reached the peak till 3rd week during the CNV development. The protein levels of VEGF and TNF-α also increased significantly in CNV mice, which were inhibited by a synthetic TGF-β inhibitor LY2157299 or a natural TGF-β inhibitor Decorin. The phosphorylated Smad2/3 levels increased significantly in CNV mice, but this response was profoundly suppressed by the TGF-β inhibitors. Here we have demonstrated that TGF-β/Smad signaling plays an important role in Laser-induced CNV formation through down-regulation of VEGF and TNF-α expressions, suggesting TGF-β inhibitors may provide an alternative to traditional methods in wet AMD treatment.

Age-related macular degeneration (AMD) is the most common cause of irreversible blindness and an improving public health problem due to aging population in the developed world1, 2. Factors implicated in AMD include age, genetic predisposition, oxidative stress, diet, smoking and activation of complement3. Two forms of AMD are recognized as nonexudative (dry) and exudative (wet) types. Dry AMD is characterized by the presence of drusen, debris accumulated underneath the retina, pigmented changes and geographic atrophy in some eyes (GA)4. In contrast, wet AMD is characterized by aberrant angiogenesis within the subretinal space, referred to as choroid neovascularization (CNV) or retinal angiomaticous proliferation (RAP) within the retina, and usually causes severe and rapid vision loss5. CNV is the most severe complication and the hallmark of wet AMD, these vessels usually break through Bruch’s membrane to enter the subretinal space, causing retinal pigment epithelium (RPE) detachment, subretinal or intraretinal hemorrhage, fibrovascular scarring, resulting in retinal tissue damage and loss of vision5.

Although CNV angiopoiesis is a series of complex pathological processes and still remains unclear, experimental and clinical studies have revealed that a variety of cytokines, chemokines and endothelial adhesion molecules play crucial roles in the development of CNV5-4. Several angiogenic factors, such as vascular endothelial

1Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, PR China.
2Department of Neurobiology and Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, PR China. 3Beijing Stomatological Hospital, Capital Medical University, Beijing, 100050, PR China. Xiaolei Wang and Wei Ma contributed equally to this work. Correspondence and requests for materials should be addressed to X.W. (email: wangxleye@ccmu.edu.cn) or J.L. (email: junfali@ccmu.edu.cn)
growth factor (VEGF), platelet-derived growth factor (PDGF), angiopoietin, stromal derived factor (SDF)-1, b-fibroblast growth factor (FGF), pigment epithelium-derived factor (PEDF) and thrombospordin-1 were confirmed to be key molecules in pathological angiogenesis. The increased expression of VEGF in CNV has been identified, and the VEGF inhibition is a highly effective treatment in wet AMD. In clinical practice, wet AMD patients are currently treated with intravitreal anti-VEGF agents including Lucentis (Ranibizumab), Eylea (Aflibercept) and bevacizumab (avastin). However, these treatments have various limitations such as the requirement of repeat intravitreal injections. Furthermore strategies targeting only one of multiple angiogenic factors are not sufficient to control the disease process. Thus, development of an alternative strategy to achieve combination therapy that blocks other signaling pathways is more likely to produce a greater therapeutic benefit for wet AMD.

Recently, there is increasing evidence that indicates some inflammatory cytokines such as interleukin (IL)-1 and IL-6, tumor necrosis factor (TNF)-α and transforming growth factor beta (TGF-β) have an effect on CNV. The TGF-β superfamily comprises a large number of multifunctional polypeptides that participate in many diverse biological processes, including cell proliferation, differentiation, neuronal growth, angiogenesis, inflammation, fibrotic processes and immune surveillance. TGF-β is a pleiotropic cytokine that binds to membrane receptors bearing serine/threonine kinase activity, namely TGF-β receptors type I and type II, which were located in the retinal ganglion cell layer and Müller glia in mouse retina, and signals through both Smad-dependent and Smad-independent pathways. In retina, TGF-β is produced by RPE cells and pericytes, and the increased intravitreal transforming growth factor beta 1 (TGF-β1) levels appear to be related to retinal angiogenesis. While TGF-β has been shown to be able to induce angiogenesis in vivo, the mechanisms are not well defined. It has been reported that TGF-β may significantly stimulate strong VEGF secretion in human RPE cell cultures. In addition, TGF-β has also been implicated in angiogenesis as a regulator of endothelial cell proliferation and macrophage infiltration as well as deposition and proteolytic remodeling of extracellular matrix (ECM), resulting in activated angiogenesis and vascular remodeling.

Considering the crucial roles of TGF-β in neovascularization, we hypothesize that TGF-β may work in concert with other cytokines in VEGF up-regulation, and selective blockade of TGF-β would abate CNV development. To test this hypothesis, the Laser photocoagulation was applied to establish the experimental CNV mouse model to mimic wet AMD. The changes of TGF-β, TNF-α and VEGF protein expressions, as well as Smad2/3 phosphorylation levels were observed in RPE-choroid complex of mice after Laser-induced CNV formation. In addition, two TGF-β specific inhibitors LY2157299 and Decorin were used to determine whether TGF-β inhibition could prevent the formation of CNV. We found that TGF-β/Smad pathway through regulation of pro-angiogenic factors played a critical role in the development of experimental CNV, suggesting TGF-β/Smad signaling pathway blockage may provide a novel, effective auxiliary treatment for AMD.

Materials and Methods

Male C57BL/6j mice at age of 6–8 weeks old and weighing 20–25 g were used in the study. Animals were housed in metal breeding cages with free access to food and water in a room with a 12-h/12-h light/dark cycle. The humidity and temperature were maintained at 55% and 23 °C, respectively. All the animal procedures were performed with strict adherence to the guidelines set by the Animal Care and Use Committee of Capital Medical University (SCXK[Jing] 2016-0011) and the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The experimental protocols were approved by Capital Medical University licensing committee. All reasonable efforts were made to minimize suffering. Except for individually indicated agents and antibodies in the text, all chemicals were purchased from Sigma-Aldrich (St. Louise, MO 63103, USA).

Laser-induced CNV and Drug Treatment. Anesthesia was induced by intraperitoneal injection of pentobarbital (0.05 mg/g body weight), and pupils were dilated with topical 5% tropicamide (Santen, Osaka, Japan). Following mydriasis, mice were placed on a platform under the slit lamp, and the corneas were anesthetized with 0.5% proparacaine hydrochloride eye drops (Alcon Laboratories, Elkhridge, MD 21075, USA). Laser photocoagulation (532 nm laser, 120 mW, 100 ms duration, 50 μm spot size) was performed bilaterally in each mouse. Laser spots were applied in a standard fashion around the optic nerve using a slit lamp delivery system (Lumenis 1000, Salt Lake City, UT 84104, USA) with a handheld cover slip as a contact lens. Photocoagulation lesions (4–6/eye) were delivered in a peripapillary distribution at a distance of 1- to 2-disc diameters from the optic nerve, avoiding major vessels. The appearance of a cavitation bubble by laser treatment, which indicates disruption of Bruch’s membrane, is an important factor in obtaining CNV; therefore, only burns in which a bubble was produced were included in subsequent experiments. Spots containing hemorrhage or failing to develop a bubble at the laser site were excluded from the analysis. The eye was subsequently coated with erythromycin eye ointment. The experimentally sham treated mice were assigned as normal (Nor) control.

To investigate the effect of TGF-β inhibitor on the formation of CNV, mice were randomly assigned to treatment and sham control groups. The TGF-β inhibitor LY2157299 (S232; Selleck, Houston, TX 77230, USA), a new and potent specific TGF-β type I receptor inhibitor of the family of pyrazoles, was dissolved in dimethylsulfoxide (DMSO) and diluted with phosphate buffered saline (PBS, 0.07% DMSO). Right after Laser injury, LY2157299 was delivered to mice by intraperitoneal injection with the dose of 1.5, 3.0 and 6.0 μg/g body weight per day or the same volume of vehicle (0.07% DMSO) for 7 days, 14 days, 21 days and 28 days to evaluate the inhibitory effect on CNV size. Based on preliminary results, 3.0 μg/g LY2157299 was used for all the experiments. This study also evaluates the effect of Decorin, a naturally occurring TGF-β inhibitor. Decorin (D-8428; Sigma-Aldrich, St. Louis, MO 63103, USA) was dissolved in PBS and diluted to reach a final dose of 10 μg/µl. After the photocoagulation, a 1 μl intravitreal injection of decorin or control PBS was administered using a microliter syringe.
**Fundus Photography and Fundus Fluorescein Angiography.** One week after Laser photocoeagulation, fundus examinations were performed under systemic anesthesia and pupil dilation using a digital fundus camera (Heidelberg Retina Angiograph II, Heidelberg Engineering, Heidelberg, Germany), and the Laser lesions were studied using fundus fluorescein angiography (FFA) to evaluate CNV development. FFA images were taken at 2–5 min after intraperitoneal injection of 0.1 ml of 2.5% fluorescein sodium (Alcon, Houston, TX 77054-1309, USA).

**Analysis of Lesion Area in RPE/choroid Flat Mounts.** One to four weeks after the CNV Laser procedure, mice were euthanized by cervical dislocation and eyes were enucleated and fixed at 4% paraformaldehyde solution for 1–2 h. Flat mounts of RPE-choroid complex were obtained by removing the anterior segments and the neural retina under an operation microscope. Then retinal and choroid tissues were washed in PBS containing 1% BSA, 0.2% Tween-20 (AppiChem GmbH, Darmstadt 64291, Germany) and 0.1% Triton-X 100. Eyecups were incubated with 0.5% fluorescein-isothiocyanate (FITC)-isolectin B4 (Vector Laboratories Inc., Burlingame, CA 94010, USA) overnight at 4°C to label invading choroid vessels and then washed in PBS three times. After staining, the eyecups were flattened by four to six radial cuts from the edge to the equator and flat mounted with the scleral side facing down onto a microscope slide. The flatmounts were analyzed with fluorescence microscope (Olympus, Hamburg, Germany). The size of FITC-isoelecin B4 positive CNV areas was quantified with Olympus CellF software. Lesions with obvious hemorrhage or bridging CNV were excluded. Images were measured and confirmed by two reviewers in a masked procedure.

**Western Blot Analysis.** Antibodies used in this study are listed as follows: rabbit anti-TGF-β polyclonal antibody (1:500; catalogue number ab66043), rabbit anti-VEGF polyclonal antibody (1:1,000; catalogue number ab46154) and rabbit anti-TNF-α polyclonal antibody (1:500; catalogue number ab9635, Abcam, Cambridge, UK); rabbit anti-Smad2/3 polyclonal antibody (1:1,000; catalogue number #5678) and anti-Phospho-Smad2/3 monoclonal antibody (1:1,000; catalogue number #8828, Cell Signaling Technology, Boston, MA 02241–3843, USA); mouse anti-β-actin monoclonal antibody (1:3,000; Sigma-Aldrich Corp. St. Louis, MO 63103, USA); and the horseradish peroxidase conjugated goat anti-rabbit or anti-mouse IgG as secondary antibody (1:4,000; Stressgen Biotechnologies Corporation, Victoria BC, Canada).

**Histopathological Examination and Immunohistochemistry.** After each animal was sacrificed by cervical dislocation, the eyeballs were enucleated and fixed at 4% paraformaldehyde solution, conventionally dehydrated and embedded in paraffin wax. The optic nerve parallel to the sagittal plane at the Laser photocoagulation position was selected, and slices with a thickness of 6.0 μm were prepared continuously. The sections were stained with hematoxylin-eosin (HE), and then were observed and photographed under a light microscope.

**Statistical Analyses.** Data are expressed as mean ± SEM. Significant differences between groups were determined by one-way ANOVA in combination with all pair wise multiple comparison procedures using Bonferroni test. In all cases, values of p < 0.05 were considered as statistically significant.

**Results**

**Increased CNV Formation in the Retina of Mice after Laser Injury.** One week after Laser photocoeagulation, fundus photographs and fundus fluorescein angiography (FFA) were carried out in experimentally sham treated normal control (Nor) and experimental (Laser) mice to examine CNV formation and fluorescein leakage (Fig. 1A–D). The Laser spots showed a central depigmented crater surrounded by irregular hyperpigmentation in fundus photograph and evident fluorescein leakage in FFA, which indicated CNV formation at one week after Laser injury.

The histological analysis of retina stained with HE (Fig. 1E and F) also confirmed that the CNV began to form on day 7 after Laser-induced rupture of Bruch’s membrane. Damages to the RPE, outer nuclear layer, outer plexiform layer and inner nuclear layer were seen in all CNV lesions, and the newly formed fibrovascular complex, which consisted of collagen fibers, fibroblasts, endothelial cells, RPE cells and newly formed vessels, extended towards the subretinal space (Fig. 1F). Flattened areas of tissue were evaluated to determine the area of clearly demarcated isoelecin positive CNV from one to four weeks post-laser injury, which showed the time course of CNV formation in Table 1. The mean CNV area was 11933.20 ± 2894.39 μm² at day 7, and then significantly increased at day 14 (24313.99 ± 3308.46 μm²), day 21 (30932.12 ± 3308.46 μm²), and day 28 (33075.49 ± 2585.29 μm²) (P < 0.05) in the retina of mice post-laser injury.

**Increased TGF-β Expression in the Retina Following Laser-induced CNV Formation.** As shown in Fig. 2A, the immunofluorescence staining results indicated that TGF-β staining was weakly observed.
Figure 1. Morphological evaluation of mouse fundus at one week after Laser injury. The typical results of fundus photographs (A,B) and fundus fluorescein angiography (FFA, C,D) revealed that there were hyperfluorescence leakage in the Laser injured spots (white arrows) of fundus at one week after photocoagulation; the hematoxylin–eosin (HE) staining results (E,F, scale bar = 50 μm) showed that Laser-induced CNV presented vascular plexus with wide blood vessel lumen, which originated from the choroid and grew towards the bottom of the retina (black arrows) when compared with that of experimentally normal (Nor) control (sham treated).
in the retinal ganglion cells and choroid of normal control mice, while the TGF-β protein expression remained at high level in the ganglion cell layer, outer nuclear layer, inner nuclear layer and choroid of mice after 2-weeks photocoagulation. Furthermore, the TGF-β protein expression levels in retina-choroid complex during the development of laser-induced CNV formation was determined by using Western blot (Fig. 2B). The quantitative analysis results in Fig. 2C demonstrated that the protein expression levels of TGF-β increased significantly [F(4,20) = 28.025, p < 0.05, n = 5 per group] from 1 to 4 weeks and reached the peak at day 21 in the retina-choroid complex of mice after Laser-induced CNV formation when compared with that of normal controls.

### Effect of LY2157299 on VEGF and TNF-α Protein Expression and Smad2/3 Phosphorylation Levels in Retina Following Laser-induced CNV Formation

TGF-β protein expression level is elevated in the RPE and choroidal blood vessels of AMD patients and may promote the occurrence of angiogenesis by regulating the activity of vascular endothelial cells and the expression of VEGF. To elucidate whether TGF-β affects angiogenic and inflammatory molecules related to the CNV formation, the effect of TGF-β type I

| Time (d) | Case Numbers | Light spots | Area of CNV (μm², x ± s) | Increased multiple of CNV area |
|----------|--------------|-------------|--------------------------|-------------------------------|
| 7        | 4            | 48          | 11933.20 ± 2041.07       | 1.00                          |
| 14       | 4            | 48          | 24313.99 ± 3308.46       | 2.04                          |
| 21       | 4            | 48          | 30932.12 ± 2894.39       | 2.59                          |
| 28       | 4            | 48          | 33075.49 ± 2585.29       | 2.77                          |

Table 1. Assessment of Laser-induced choroid neovascularization (CNV) formation through fluorescein-isothiocyanate (FITC)-isolectin B4 staining in RPE/choroid flat mounts of mice.

Figure 2. Increased expression of TGF-β in retina of mice after Laser-induced CNV formation. (A) Flat mounts were fluorescently labeled with TGF-β antibody (green) and the nuclear staining with Hoechst (blue). Low levels of TGF-β expression were detected in ganglion cells of retina and choroid of Nor control mice. However, the strong immunoreactivity could be observed in the ganglion cells, outer nuclear layer, inner nuclear layer of retina and choroid at two weeks after Laser injury (Scale bars = 50 μm). (B) Typical result of Western blot showed changes of TGF-β protein levels in RPE/choroid/sclera isolated from the mice with or without Laser-induced CNV formation. (C) The quantitative analysis results demonstrated that the TGF-β protein levels were significantly up regulated at one week and reached a peak at three weeks in RPE/choroid/sclera of mice after Laser photocoagulation. The β-actin was used as loading control and reference protein, and the ratio of TGF-β/β-actin in Nor mice was set as 100%. *P < 0.05 vs Nor, n = 5 per group.
receptor-specific inhibitor LY2157299 on VEGF and TNF-α protein expression and Smad2/3 phosphorylation levels were determined in retina during CNV formation.

As shown in Fig. 3A–C, the protein expression levels of growth factor VEGF and pro-inflammatory cytokine TNF-α were significantly upregulated (p < 0.05, n = 5 per group) in the retina at 1–4 weeks after laser injury and PBS treatment. However, the TGF-β inhibitor LY2157299 could significantly inhibit VEGF and TNF-α protein expression and Smad2/3 phosphorylation levels were determined in retina during CNV formation.

Figure 3. Effect of TGF-β inhibitor LY2157299 on the levels of VEGF and TNF-α protein expression and Smad2/3 phosphorylation in RPE-choroid complex of mice after Laser-induced CNV formation. (A) The typical result of Western blot showed changes of VEGF and TNF-α protein expressions. The quantitative analysis results demonstrated that the protein expression levels of VEGF (B) and TNF-α (C) were significantly elevated and peaked at 3–4 weeks following CNV induction, but TGF-β chemical inhibitor LY2157299 (intraperitoneal injection, 3.0 μg/g BW) treatment could significantly suppress the increase of VEGF and TNF-α protein expressions in RPE-choroid complex of mice at 1–4 weeks after Laser-induced CNV formation. (D) The representative result of Western blot showed the effect of LY2157299 on Smad2/3 phosphorylation and TGF-β protein expression levels in RPE-choroid complex of Laser-treated mice. The quantitative analysis results indicated that LY2157299 could significantly inhibit the increase of p-Smad2/Smad2 (E) and p-Smad3/Smad3 (F) levels in RPE-choroid complex of mice at 2–3 weeks after Laser-induced CNV formation.*P < 0.05 vs Nor; *P < 0.05 vs corresponding PBS treatment; n = 5 per group.
expressions in the retina at 2–4 weeks when compared with that of PBS controls during the development of Laser-induced CNV formation (p < 0.05, n = 5 per group).

In addition, the levels of phosphorylated Smad2/3 (P-Smad2/3, Fig. 3D–F) increased significantly (p < 0.05, p = 5 per group) in the retina at 2–3 weeks after Laser injury and PBS treatment when compared with that of normal control. Similarly, the increase of P-Smad2/3 was significantly suppressed (p < 0.05, n = 5 per group) in the retina at 2–3 weeks after Laser injury and LY2157299 treatment. These results suggest that TGF-β-Smad signaling pathway may be involved in the high expressions of VEGF and TNF-α in retina following Laser-induced CNV formation.

**Effect of Decorin on VEGF and TNF-α Protein Expression and Smad2/3 Phosphorylation Levels in Retina Following Laser-induced CNV Formation.** TGF-β natural inhibitor Decorin has the same effect with LY2157299 in blocking the laser-induced expression of VEGF, TNF-α and Smad2/3. As shown in Fig. 4A–C, Decorin treatment could significantly suppress the increase of VEGF and TNF-α protein expressions in RPE-choroid complex of mice at 1–4 weeks after Laser-induced CNV formation (p < 0.05, n = 5 per group). And besides, Fig. 4D–F indicated that Decorin could significantly inhibit the increase of P-Smad2/3 levels in RPE-choroid complex of mice after Laser-induced CNV formation (p < 0.05, n = 5 per group). The TGF-β protein levels were significantly suppressed in RPE-choroid complex of mice after Decorin treatments (p < 0.05, n = 5 per group).

**Effects of LY2157299 and Decorin on Laser-induced CNV Formation in Retina of Mice.** To further determine the involvement of TGF-β/Smad in retinal CNV formation through regulation of the inflammatory and angiogenic factors that promote neovascularization, the effects of TGF-β chemical inhibitor LY2157299 and natural inhibitor Decorin on Laser-induced CNV formation were observed in the retina of mice. The C57BL/6 mice, right after Laser injury were intraperitoneally injected either with 1.5, 3.0, 6.0 μg/g BW of LY257299 or PBS containing 0.07% DMSO in the controls. As shown in Fig. 5A–E, the isolecitin-B4 staining results of RPE/choroid flat mounts indicated that 3.0–6.0 μg/g BW of LY257299 could significantly (P < 0.05, n = 5 per group) reduce the neovascular area in retina of mice at day 14 after Laser-induced CNV formation when compared with that of PBS treated control groups. In addition, the effect of a naturally occurring TGF-β inhibitor Decorin (10 μg in 1 μl PBS, intravitreal injection) on the development of CNV after Laser photocoagulation was determined by using fluorescence leakage and isolecitin-B4 staining areas. The representative FFA images showed that both LY257299 (3.0 μg/g BW intraperitoneal injection, Fig. 6B) and Decorin (10 μg intravitreal injection, Fig. 6C) could reduce fluorescein leakage when compared to the eyes treated with PBS (Fig. 6A) at day 14 after Laser photocoagulation. As shown in Fig. 6D–I, the quantitative analysis results of RPE/choroid flat mounts stained with isolecitin-B4 also demonstrated significant reduction (P < 0.05, n = 5 per group) in CNV formation areas in retina for both LY2157299 and Decorin treatments when compared with that of their corresponding PBS control mice at day 14 after Laser-induced CNV formation.

**Regression of Established CNV after Decorin Treatment.** To test if TGF-β inhibitor attenuate CNV development after neovascularization has started, the CNV area was measured in a cohort of mice at day 7 after Laser-photocoagulation to provide the baseline (Fig. 7A). The intravitreal injections of Decorin (10 μg in 1 μl PBS) or PBS were initiated at day 7 after Laser-photocoagulation, and then additional week later, the CNV areas on RPE/choroid flat mounts stained with isolecitin B4 were analyzed (Fig. 7B and C). The quantitative analysis results (Fig. 7D) revealed that the mean CNV area in eyes treated with Decorin was significantly less than those seen in Baseline and PBS treated control eyes (P < 0.05, n = 5 per group), suggesting a regressive effect of Decorin on established CNV. These data demonstrated that TGF-β inhibitor Decorin could inhibit Laser-induced CNV formation whether administered prior to or after the onset of angiogenesis.

**Discussion**

Wet AMD with the hallmark presence of CNV is one of the main causes of blindness in the world. Understanding the mechanisms of CNV etiopathology could have a better impact on the health and quality of life of patients with wet AMD. Intravitreal injection of anti-VEGF antibody is currently considered the gold standard therapy for CNV, albeit with over 60% of AMD patients do not have improved vision after the treatment. In addition, some commonly used treatments, such as Laser photocoagulation, photodynamic therapy or intravitreal administration of triamcinolone, also have limited efficacy and severe side effects, other alternative therapeutic strategies are being sought.

As Laser-induced CNV by a rupture of Bruch’s membrane shares many of the same pathologic steps with neovascularization; arises from varied causes, we utilized this in vivo model to evaluate the effect of TGF-β signaling pathway because it has been shown to possess some actions including inflammatory and angiogenesis. Laser lesions showed the progressive subretinal ingrowth of new vessels from the early onset at one week up to peak at four weeks after photocoagulation. Using the mouse model of CNV, we demonstrated the relationship between TGF-β signaling and CNV. We observed that local expression of TGF-β in the retina-choroid complex suppressed to Laser-induced CNV is upregulated during experimental CNV development, but there was a low expression level in the normal mice. Administration of the TGF-β inhibitors prior to or after the onset of angiogenesis potentially attenuated CNV lesion size, which was associated with suppressing the levels of Smad2/3 phosphorylation and the expressions of VEGF and TNF-α in the injured eye. Our results suggest that TGF-β/Smad signaling pathway inhibition have potential implications for the novel therapeutic of wet AMD, different to that of current treatments for CNV lesions.
Neovascularization is regulated by complex interactions among numerous cytokines and growth factors in a highly orchestrated manner, which has become a major area of research in recent years. Although the pathogenesis underlying CNV has not been fully elucidated, increasing experimental and clinical studies have revealed that this multifactorial process involves multiple molecules, including inflammatory cells and cytokine networks. These elements may come from the serum as a consequence of blood-ocular barrier breakdown, or from infiltrating leucocytes and resident cells in diseased ocular tissue\(^2\). The CNV tissues from human surgical extracted...
samples and the rodent Laser-induced models express high levels of proangiogenic molecules and decreased production of angiogenic inhibitors. Studies confirm that VEGF is the central link in promoting angiogenesis in the development of CNV and other retinal neovascularization disorders. However, there remain some questions as to why VEGF inhibitions are only partially effective. Apart from VEGF, many other cytokines and growth factors contribute to CNV either directly via activation of their cognate receptors or indirectly via crosstalk with VEGF and other signaling pathways. More recently, studies have been directed towards other mediators, among which is TGF-β. TGF-β is a multifunctional regulator in the retina that participates in pathological angiogenesis and neovascularization. It regulates expression of a lot of genes in epithelial cells (ECs), particularly those involved in establishment of, and interaction with, the basement membrane (BM).

Figure 5. TGF-β inhibitor LY2157299 could dose-dependently inhibit the Laser-induced CNV formation at in RPE-choroid-sclera complex of mice. The representative images showed CNV staining with isoelectin-B4 in the RPE-choroid-sclera complex of Laser-treated mice at 2 weeks after intraperitoneal injections of PBS (A) and LY2157299 at 1.5 (B), 3.0 (C) and 6.0 μg/g BW (D). (E) The statistical results suggest that LY2157299 (3.0–6.0 μg/g BW) could significantly inhibit Laser-induced neovascular growth when compared with that of PBS treatment. *P < 0.05 vs PBS treatment; bars = 100 μm; n = 5 per group.

The TGF-β mRNAs expression during the process of neovascularization could be detected in retinal pigment ECs, fibroblast-like cells and the endothelium of the neovascular region. We report here that TGF-β protein expression is up regulated during Laser-induced CNV development. TGF-β has a crucial role in the formation of extracellular matrix. It executes the production of matrix molecules and represses matrix degradation by stimulation of protease inhibitor synthesis and inhibition of proteases synthesis. The up-regulation of TGF-β strongly suggested that it could be involved in the accumulation of extracellular deposits such as drusen. Previous reports have revealed that TGF-β strongly enhanced VEGF mRNA expression and protein secretion, and synergistically associated with TNF-α over VEGF transcription. Some studies also confirmed that TNF-α is a pleiotropic cytokine which mediates angiogenic and inflammatory effects in the cells involved in the formation of CNV.

Furthermore, TGF-β activation may contribute to the inflammatory cell-induced neovascularization since it is highly potent chemotactic agents for monocytes. These findings led us to speculate that TGF-β may work in concert with other cytokines in VEGF up-regulation, and surmise that selective blockage of TGF-β would prevent the formation of CNV. In this study, we found that the Laser injury-induced increase of TNF-α and VEGF protein expressions could be suppressed by TGF-β blockage during CNV progression, and the TGF-β chemical inhibitor LY2157299 and natural inhibitor Decorin could prevent CNV formation and improve its regression, suggesting that TGF-β is a critical trophic factor for the expression of aberrant neovascularization.

In addition, we further explored the possible pathways through which TGF-β promotes neovascularization. Studies provide evidences that TGF-β signal transduction includes both specific Smad-dependent and Smad-independent pathways that can be activated by the TGF-β receptors via either phosphorylation or direct interaction. Briefly, the canonical intracellular TGF-β/Smad signaling initiates its regulatory functions binding to the TβRII located in the cell membrane, the constitutively active TβRII activates TβRI, which phosphorylates downstream regulatory Smad2/3. Then the phosphorylated Smad2/3 oligomerize with the Smad4 and form the Smad complex, which translocate into the nucleus in combination with transcription factors. A series of previous reports have indicated that TGF-β signaling promotes tumor formation and angiogenesis. But on the contrary to the above findings, TGF-β has been shown to play a tumor suppressing role through many different mechanisms including inhibition of cell proliferation and induction of apoptosis. To these studies, it has shown that TGF-β plays a dual role in tumor. Such complexity regulation of this differential signaling is contingent on the concentration of TGF-β, the presence or absence of other regulatory factors and the cells types. Our current results showed that TGF-β/Smad pathway may function as an angiogenesis promoter in CNV development, and...
the injection of TGF-β type I receptor inhibitor LY2157299 [a new type I receptor TGF-β kinase antagonist\(^2\)] resulted in significantly inhibition of phosphorylated Smad 2/3. However, this treatment did not further change TGF-β expression. We noticed that there is a continuous increasing of TGF-β, VEGF and TNF-α with the peak at 3–4 weeks post-laser, the same time interval required for the onset of neovascularization. The suppression of activated Smad 2/3 is consistent with the results of the significant decrease in protein expressions of pro-angiogenic molecules including VEGF and TNF-α. This supports the hypothesis that LY2157299 suppresses CNV development via inhibition of the TGF-β/Smad pathway, and the possible effects of TGF-β on neovascularization may involve inducing the accumulation of TNF-α, in addition to stimulating VEGF overexpression by the RPE. In fact, Smad pathway is integrated into a signaling cross-talk network, involved in a variety of other signaling pathways. Much remains to be elucidated regarding this mechanism. In conclusion, the results firstly demonstrated that TGF-β/Smad signaling plays an important role in angiogenesis of Laser-induced CNV formation of wet AMD. TGF-β inhibition by its specific inhibitors LY2157299 and Decorin is able to reduce CNV progression through the Smad signaling pathway, which was achieved through

**Figure 6.** TGF-β inhibitors LY2157299 and Decorin could suppress the Laser-induced CNV formation in RPE-choroid-sclera complex of mice. The representative FFA images showed the fluorescence leakage in eye fundus of vehicle (A), TGF-β chemical inhibitor LY2157299 (intraperitoneal injection of 3.0 µg/g BW, B) and TGF-β natural inhibitor Decorin (intravitreal injection of 10 µg in 1 µl PBS, C) treated mice at 2 weeks after Laser photocoagulation (white arrowheads indicated Laser-injured spots). Fluorescein leakage was reduced and no abnormalities were observed in the retinal blood vessels of Laser-injured mice after LY2157299 and Decorin treatments. The isoclectin-B4 stained images showed the changes of CNV area in RPE-choroid flat mounts of mice following Laser injury only (D), intraperitoneal injection of PBS (E) and LY2157299 (G), and intravitreal injection of PBS (F) and Decorin (H) at 2 weeks after photocoagulation. Red dotted lines indicate CNV lesions (bar = 100 µm). (I) The areas of CNV lesions were quantified by using digital imaging analysis, and showed that the CNV size was significantly suppressed by both LY2157299 and Decorin treatments when compared with that of controls. *P < 0.05 vs corresponding PBS treatment; n = 5 per group.
down-regulation of VEGF and TNF-α. These results suggest that TGF-β inhibitors have great potential in wet AMD treatment, providing an alternative to traditional methods in the clinical field and merits further investigation by in vivo studies.

References
1. Ryskulova, A. et al. Self-reported age-related eye diseases and visual impairment in the United States results of the 2002 national health interview survey. *American journal of public health* 98, 454–461, doi:10.2105/AJPH.2006.098202 (2008).
2. Tomany, S. C. et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. *Ophthalmology* 111, 1280–1287, doi:10.1016/j.ophtha.2003.11.010 (2004).
3. Birke, K., Lipo, E., Birke, M. T. & Kumar-Singh, R. Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration. *PLoS one* 8, e76766, doi:10.1371/journal.pone.0076766 (2013).
4. Freund, K. B., Mrejen, S. & Gallego-Pinazo, R. An update on the pharmacotherapy of neovascular age-related macular degeneration. *Expert opinion on pharmacotherapy* 14, 1017–1028, doi:10.1517/14656566.2013.787410 (2013).
5. Rattner, A. & Nathans, J. Macular degeneration: recent advances and therapeutic opportunities. *Nature reviews. Neuroscience* 7, 860–872, doi:10.1038/nrn2007 (2006).
6. Semkova, I. et al. Anti-angiogenic effect of the basement membrane protein nidogen-1 in a mouse model of choroidal neovascularization. *Experimental eye research* 118, 80–88, doi:10.1016/j.exer.2013.11.006 (2014).
7. Tsutsumi, C. et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. *Journal of leukocyte biology* 74, 25–32 (2003).
8. Krystolik, M. G. et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. *Archives of ophthalmology* 120, 338–346 (2002).
9. Sakurai, E., Anand, A., Ambati, B. K., van Rooijen, N. & Ambati, J. Macrophage depletion inhibits experimental choroidal neovascularization. *Investigative ophthalmology & visual science* 44, 3578–3585 (2003).
10. Bhutto, I. A. et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. *Experimental eye research* 82, 99–110, doi:10.1016/j.exer.2005.05.007 (2006).
11. Lu, M. & Adamis, A. P. Molecular biology of choroidal neovascularization. *Ophthalmology clinics of North America* 19, 323–334, doi:10.1016/j.ocl.2006.05.001 (2006).
12. Lyzogubov, V. et al. Complement regulatory protein CD46 protects against choroidal neovascularization in mice. The American Journal of Pathology 184, 2357–2358, doi:10.1016/j.ajpath.2014.06.001 (2014).

13. Brand, C. S. Management of retinal vascular diseases: a patient-centric approach. Eye 26(suppl 2), S1–16, doi:10.1038/eye.2012.32 (2012).

14. Keane, P. A. & Sadda, S. R. Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians. Journal of ophthalmology 2012, 483034, doi:10.1155/2012/483034 (2012).

15. Shim, C. et al. Complications in patients after intravitreal injection of bevacizumab. Acta ophthalmologica 86, 372–376, doi:10.1111/j.1600-0420.2007.01067.x (2008).

16. Wu, L. et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 246, 81–87, doi:10.1007/s00417-007-0660-z (2008).

17. Zhang, P., Su, Y. & Liu, F. The relationship between intervention in the CD40 signal pathway and choroidal neovascularization. Onco Targets and Therapy 7, 263–267, doi:10.2147/OTT.S56909 (2014).

18. Nagineni, C. N. et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. Journal of cellular physiology 197, 453–462, doi:10.1002/jcp.10378 (2003).

19. Bentjen, E. et al. Transforming Growth Factor type beta and Smad family signaling in stem cell function. Cytokine & growth factor reviews 20, 449–458, doi:10.1016/j.cytogfr.2009.10.005 (2009).

20. Shi, Y. & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685–700 (2003).

21. Simo, R., Carrasco, E., Garcia-Ramirez, M. & Hernandez, C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Current diabetes reviews 2, 71–98 (2006).

22. Loukovaara, S. et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta in diabetic eyes undergoing vitrectomy. Acta ophthalmologica 91, 531–539, doi:10.1111/j.1755-3788.2012.02473.x (2013).

23. Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G. & Mignatti, P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. Journal of cellular physiology 219, 449–458, doi:10.1002/jcp.21706 (2009).

24. van Royen, N. et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 16, 432–443, doi:10.1096/fj.01-05639e2 (2002).

25. Shi, X. et al. TGF-beta/Smad3 inhibit vascular smooth muscle cell apoptosis through an autocrine signaling mechanism involving VEGF-A. Cell death & disease 5, e1317, doi:10.1038/cddis.2014.282 (2014).

26. Nunes, L. et al. Structure and activation of the large latent transforming growth factor-Beta complex. Journal of the American Optometric Association 69, 643–648 (1998).

27. Bueno, L. et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. European journal of cancer 44, 142–150, doi:10.1016/j.ejca.2007.10.008 (2008).

28. Nassar, K. et al. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 249, 1649–1660, doi:10.1002/j.1469-0114.2010.tb02915.x (2010).

29. Burgao, E. et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 249, 1649–1660, doi:10.1002/j.1469-0114.2010.tb02915.x (2010).

30. Lu, H. et al. IKK2 inhibition attenuates laser-induced choroidal neovascularization. PLoS one 9, e87530, doi:10.1371/journal.pone.0087530 (2014).

31. Zarranz-Ventura, J. et al. Twenty-four-hour safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 249, 1649–1660, doi:10.1002/j.1469-0114.2010.tb02915.x (2010).

32. Ruiz-Moreno, J. M., Montero, J. A. & Zarbin, M. A. Photodynamic therapy and high-dose intravitreal triamcinolone to treat subfoveal choroidal neovascularization: P17 and P144 peptides. European journal of ophthalmology 24, 35–39, doi:10.1016/j.ejo.2013.06.016 (2017).

33. Zarranz-Ventura, J. et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. Journal of cellular physiology 197, 453–462, doi:10.1002/jcp.10378 (2003).

34. Nagineni, C. N. et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. Journal of cellular physiology 197, 453–462, doi:10.1002/jcp.10378 (2003).

35. Xie, P. et al. Transformation of TGF-beta type II receptor and actions on fibroblasts. Journal of cellular physiology 188, 160–165, doi:10.1002/jcp.10109 (2001).

36. Drabsch, Y. & ten Dijke, P. TGF-beta signalling and its role in cancer progression and metastasis. Cell 132, 379–390, doi:10.1016/j.cell.2007.11.017 (2008).

37. Xie, P. et al. Transformation of TGF-beta type II receptor and actions on fibroblasts. Journal of cellular physiology 188, 160–165, doi:10.1002/jcp.10109 (2001).

38. Nagineni, C. N. et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. Journal of cellular physiology 197, 453–462, doi:10.1002/jcp.10378 (2003).

39. Xie, P. et al. Transformation of TGF-beta type II receptor and actions on fibroblasts. Journal of cellular physiology 188, 160–165, doi:10.1002/jcp.10109 (2001).

40. Wang, X. et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 499, 306–311, doi:10.1038/nature12345 (2013).

Acknowledgements
This work was supported by the grants from the Seed Grant of International Alliance of Translational Neuroscience (PXM2014-014226-000006), Beijing Natural Science Foundation (7141001), National Natural Science Foundation of China (31171147 and 31471142), and Beijing Ophthalmology & Visual Sciences Key Laboratory (2015YJ302).

Author Contributions
X.W. and J.L. contributed to the conception and design of the study; W.M. and S.H. contributed to the acquisition of data; Z.M. and L.Z. contributed to the analysis of data; Y.Y. and Y.W. made the tables and figures; X.W. wrote the manuscript; J.L. revised the manuscript; All authors reviewed and approved the final version of the manuscript.

Additional Information
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017